

RAYMED LABS LIMITED

CIN: L24111UP1992PLC014240

Reg. off.-103 Emperor 1, Supertech Emerald Court, Sector 93A Noida,

UP – 201304, Website- www.raymedlab.com

E-mail- raymedlabs@rediffmail.com, Phone no. - 0120-2426900, 9412700300

To,

BSE Limited

Phiroze Jeejeebhoy Towers,

Dalal Street, Mumbai- 400001

Scrip code- 531207

Subject: Outcome of Board Meeting:

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/ Madam,

In compliance with Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform that the Board of Directors of the Company at their meeting held on Monday, 27th January, 2025 has, inter alia, considered and approved the followings items of agenda:

1. The Un-Audited Financial Results of the Company for the third quarter ended 31st December, 2024.
2. The Place for maintaining and keeping the books of accounts of the company at **201, A wing, 2nd Floor, Corporate Avenue, next to Udyog Bhavan, Sonawala Lane, Near Goregaon Station, Goregaon East, Mumbai 400063, Maharashtra.**
3. The Application for name reservation with CRC for the name change of Company from Raymed Labs Limited to Cresanto Limited or Cresanto Global Limited or any other name as may be approve by CRC.
4. Appointment of M/s. Nidhi Bajaj & Associates, Practicing Company Secretary, as the Secretarial Auditor of the Company for the Financial year 2024-25.

Disclosure of information pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, read with SEBI Circular No. SEBI/HO/CFD-PoD1/P/CIR/2023/123 dated 13th July, 2023 are attached as "Annexure-A".

5. Resignation of Mr. Ajai Goyal, Whole Time Director & CFO of the Company with immediate effect.

Disclosure of information pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, read with SEBI Circular No. SEBI/HO/CFD-PoD1/P/CIR/2023/123 dated 13th July, 2023 are attached as "Annexure-B".

RAYMED LABS LIMITED

CIN: L24111UP1992PLC014240

Reg. off.-103 Emperor 1, Supertech Emerald Court, Sector 93A Noida,
UP – 201304, Website- www.raymedlab.com

E-mail- raymedlabs@rediffmail.com, Phone no. - 0120-2426900, 9412700300

6. Resignation of Ms. Nisha Goyal, Director of the Company with immediate effect.
Disclosure of information pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, read with SEBI Circular No. SEBI/HO/CFD-PoD1/P/CIR/2023/123 dated 13th July, 2023 are attached as “Annexure-C”.
7. Resignation of Ms. Nisha Goyal, Internal Auditor of the Company with immediate effect.
Disclosure of information pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, read with SEBI Circular No. SEBI/HO/CFD-PoD1/P/CIR/2023/123 dated 13th July, 2023 are attached as “Annexure-C”.
8. Appointment of Mr. Prashant Bajaj, as Managing Director and Chief Financial officer of the Company with immediate effect.
Disclosure of information pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, read with SEBI Circular No. SEBI/HO/CFD-PoD1/P/CIR/2023/123 dated 13th July, 2023 are attached as “Annexure-D”.
9. Regularisation of Mr. Nishant Nathmal Bajaj, as the Non- Executive Director of the Company, subject to the approval of members of the company in the General meeting.
Disclosure of information pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, read with SEBI Circular No. SEBI/HO/CFD-PoD1/P/CIR/2023/123 dated 13th July, 2023 are attached as “Annexure-E”.
10. Regularisation of Mr. Hitesh Bajoria, as the Non- Executive Director of the Company, subject to the approval of members of the company in the General meeting.
Disclosure of information pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, read with SEBI Circular No. SEBI/HO/CFD-PoD1/P/CIR/2023/123 dated 13th July, 2023 are attached as “Annexure-F”.
11. Regularisation of Mr. Tushar Pandit Awate, as the Non- Executive Director of the Company, subject to the approval of members of the company in the General meeting.
Disclosure of information pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, read with SEBI Circular No. SEBI/HO/CFD-PoD1/P/CIR/2023/123 dated 13th July, 2023 are attached as “Annexure-G”.
12. Regularisation of Mrs. Urmila Hansraj Sharma, as the Non- Executive Director of the Company, subject to the approval of members of the company in the General meeting.
Disclosure of information pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, read with SEBI Circular No. SEBI/HO/CFD-PoD1/P/CIR/2023/123 dated 13th July, 2023 are attached as “Annexure-H”.

RAYMED LABS LIMITED

CIN: L24111UP1992PLC014240

Reg. off.-103 Emperor 1, Supertech Emerald Court, Sector 93A Noida,
UP – 201304, Website- www.raymedlab.com

E-mail- raymedlabs@rediffmail.com, Phone no. - 0120-2426900, 9412700300

13. Shifting of Registered office of the Company from the State of Uttar Pradesh to State of Maharashtra, subject to the approval of members of the company in the General meeting.

Further, please find enclosed a copy of the un-audited financial results of the Company as per Indian Accounting Standards (IND AS) for the third quarter ended 31st December, 2024 along with Limited review Report thereon as per the prescribed format pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The unaudited Financial Results for the third quarter ended 31st December, 2024 along with Limited Review Report will be made available on the Company's website

The meeting commenced at 04:00 p.m. and concluded at 07:45 p.m.

For RAYMED LABS LIMITED

(Prashant Nathmal Bajaj)

Director

DIN: 06634046

Date: 27th January, 2025

Place: Mumbai

RAYMED LABS LIMITED

CIN: L24111UP1992PLC014240

Reg. off.-103 Emperor 1, Supertech Emerald Court, Sector 93A Noida,

UP – 201304, Website- www.raymedlab.com

E-mail- raymedlabs@rediffmail.com, Phone no. - 0120-2426900, 9412700300

“Annexure A”

Disclosure of information pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, read with SEBI Circular No. SEBI/HO/CFD-PoD1/P/CIR/2023/123 dated 13th July, 2023

| Sr. No. | Particulars | Information |
|---------|--|---|
| 1. | Name of the Secretarial Auditor | M/s. Nidhi Bajaj & Associates |
| 2. | Reason for change viz. appointment, resignation, removal, death or otherwise | Appointment |
| 3. | Date of appointment/ cessation and term of appointment | Appointment of M/s. Nidhi Bajaj & Associates, Practising Company Secretaries as the Secretarial Auditor of the Company for FY 2024-25 |
| 4. | Brief Profile (in case of appointment) | M/s. Nidhi Bajaj & Associates, Practising Company Secretary Firm (Membership No. 28907, COP No. 14596) Mumbai based firm. The founder of the firm Ms. Nidhi Bajaj possesses more than 10 years of experience in Practice and her area of expertise lies in the field of legal and procedural compliances of various Acts applicable to Corporate like Companies Act 2013, SEBI and FEMA. |
| 5. | Disclosure of relationships between Directors (in case of appointment of a Director) | Not Applicable |

RAYMED LABS LIMITED

CIN: L24111UP1992PLC014240

Reg. off.-103 Emperor 1, Supertech Emerald Court, Sector 93A Noida,
UP – 201304, Website- www.raymedlab.com

E-mail- raymedlabs@rediffmail.com, Phone no. - 0120-2426900, 9412700300

“Annexure B”

Disclosure of information pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, read with SEBI Circular No. SEBI/HO/CFD-PoD1/P/CIR/2023/123 dated 13th July, 2023

| Sr. No | Particulars | Information |
|--------|--|--|
| 1. | Name of the Director | Ajay Goyal |
| 2. | Reasons for change viz. appointment, reappointment, resignation, removal, death or otherwise | Resignation |
| 3. | Date of appointment/ cessation and terms of appointment | Resigned w.e.f 27 th January, 2025 from the Post of Whole Time Director and CFO |
| 4. | Brief Profile (in case of appointment) | NA |
| 5. | Disclosure of relationships between Directors (in case of appointment of a Director) | NA |

RAYMED LABS LIMITED

CIN: L24111UP1992PLC014240

Reg. off.-103 Emperor 1, Supertech Emerald Court, Sector 93A Noida,

UP – 201304, Website- www.raymedlab.com

E-mail- raymedlabs@rediffmail.com, Phone no. - 0120-2426900, 9412700300

“Annexure C”

Disclosure of information pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, read with SEBI Circular No. SEBI/HO/CFD-PoD1/P/CIR/2023/123 dated 13th July, 2023

| Sr. No | Particulars | Information |
|--------|---|---|
| 1. | Name of the Director | Nisha Goyal |
| 2. | Reasons for change viz. appointment, reappointment, resignation, removal, death or otherwise | Resignation |
| 3. | Date of appointment/ cessation and terms of appointment | Resignation w.e.f 27 th January, 2025 from the Post of Director and Internal Auditor |
| 4. | Brief Profile (in case of appointment) | NA |
| 5. | Disclosure of relationships between Directors (in case of appointment of a Director) | NA |

RAYMED LABS LIMITED

CIN: L24111UP1992PLC014240

Reg. off.-103 Emperor 1, Supertech Emerald Court, Sector 93A Noida,

UP – 201304, Website- www.raymedlab.com

E-mail- raymedlabs@rediffmail.com, Phone no. - 0120-2426900, 9412700300

“Annexure D”

Disclosure of information pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, read with SEBI Circular No. SEBI/HO/CFD-PoD1/P/CIR/2023/123 dated 13th July, 2023

| Sr. No | Particulars | Information |
|--------|---|--|
| 1. | Name of the Director | Prashant Nathmal Bajaj |
| 2. | Reasons for change viz. appointment, reappointment, resignation, removal, death or otherwise | Appointment |
| 3. | Date of appointment/ cessation and terms of appointment | Appointment of Mr. Prashant Nathmal Bajaj as CFO of the Company w.e.f. 27 th January, 2025 and Managing Director w.e.f. 27 th January, 2025, subject to members approval. |
| 4. | Brief Profile (in case of appointment) | <p>Prashant Bajaj is the Commerce Graduate from Prahladrai Dalmia Lions College, Mumbai University and also holding the Certificate of Master of Financial Management, from N.L. Dalmia Institute of Management Studies.</p> <p>Prashant is an Entrepreneur and Business Leader with a Robust Background in the Flexible Packaging Industry. He began his career by establishing Bajaj Traders in the year 2018 aiming to revolutionize the packaging sector with innovative solutions. Before that he was Trader in Packaging Industries. Over the years, Prashant has cultivated extensive expertise in manufacturing processes, materials science, and market dynamics within the packaging industry.</p> |

RAYMED LABS LIMITED

CIN: L24111UP1992PLC014240

Reg. off.-103 Emperor 1, Supertech Emerald Court, Sector 93A Noida,
UP – 201304, Website- www.raymedlab.com

E-mail- raymedlabs@rediffmail.com, Phone no. - 0120-2426900, 9412700300

| | | |
|----|--|---|
| 5. | Disclosure of relationships between Directors (in case of appointment of a Director) | Mr. Prashant Bajaj is related to Mr. Nishant Bajaj, Additional Director on the Board. |
|----|--|---|

RAYMED LABS LIMITED

CIN: L24111UP1992PLC014240

Reg. off.-103 Emperor 1, Supertech Emerald Court, Sector 93A Noida,

UP – 201304, Website- www.raymedlab.com

E-mail- raymedlabs@rediffmail.com, Phone no. - 0120-2426900, 9412700300

“ANNEXURE – E”

Disclosure of information is pursuant to under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, read with SEBI Circular No. *SEBI/HO/CFD-PoD1/P/CIR/2023/123* date 13th July, 2023

| Sr. No | Particulars | Information |
|--------|---|--|
| 1. | Name of the Director | Nishant Nathmal Bajaj |
| 2. | Reasons for change viz. appointment, reappointment, resignation, removal, death or otherwise | Re- appointment |
| 3. | Date of appointment/ cessation and terms of appointment | Re-appointment w.e.f 27 th January, 2025 as Non- Executive Director, subject to member's approval. |
| 4. | Brief Profile (in case of appointment) | <p>Nishant Bajaj is a Law Graduate from Mumbai University, Bachelor of Commerce, and a Member of the Institute of Company Secretaries of India (ICSI). Nishant is a Corporate Law Consultant and a Trainer.</p> <p>Nishant Bajaj is working in the legal and secretarial vertical. Nishant is having vast experience in handling and advising on various company law and corporate law matters including incorporation of company, IPO, Rights Issue, Preferential Issues of securities, Board, Committees and shareholders meetings, mergers, amalgamations and restructuring of companies, certification & filing of various forms, returns and other documents with MCA, ROC, SEBI & Stock Exchanges.</p> |
| 5. | Disclosure of relationships between Directors (in case of appointment of a Director) | Mr. Nishant Bajaj is related to Prashant Bajaj Director on the Board. |

RAYMED LABS LIMITED

CIN: L24111UP1992PLC014240

Reg. off.-103 Emperor 1, Supertech Emerald Court, Sector 93A Noida,

UP – 201304, Website- www.raymedlab.com

E-mail- raymedlabs@rediffmail.com, Phone no. - 0120-2426900, 9412700300

“ANNEXURE – F”

Disclosure of information is pursuant to under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, read with SEBI Circular No. *SEBI/HO/CFD-PoD1/P/CIR/2023/123* date 13th July, 2023

| Sr. No | Particulars | Information |
|--------|--|---|
| 1. | Name of the Director | Hitesh Bajoria |
| 2. | Reasons for change viz. appointment, reappointment, resignation, removal, death or otherwise | Re- appointment |
| 3. | Date of appointment/ cessation and terms of appointment | Re-appointment w.e.f 27 th January, 2025 as Non- Executive Director, subject to member’s approval. |
| 4. | Brief Profile (in case of appointment) | Hitesh Bajoria has completed Bachelor of Science from University of Bikaner, Rajasthan. He Comes from a business-oriented family in Rajasthan. Hitesh Bajoria is a dynamic professional with a strong foundation in the Pharmaceutical Industry. |
| 5. | Disclosure of relationships between Directors (in case of appointment of a Director) | Mr. Hitesh Bajoria is not related to any Director on the Board. |

RAYMED LABS LIMITED

CIN: L24111UP1992PLC014240

Reg. off.-103 Emperor 1, Supertech Emerald Court, Sector 93A Noida,

UP – 201304, Website- www.raymedlab.com

E-mail- raymedlabs@rediffmail.com, Phone no. - 0120-2426900, 9412700300

“ANNEXURE – G”

Disclosure of information is pursuant to under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, read with SEBI Circular No. *SEBI/HO/CFD-PoD1/P/CIR/2023/123* date 13th July, 2023

| Sr. No | Particulars | Information |
|--------|--|--|
| 1. | Name of the Director | Tushar Pandit Awate |
| 2. | Reasons for change viz. appointment, reappointment, resignation, removal, death or otherwise | Re-appointment |
| 3. | Date of appointment/ cessation and terms of appointment | Re-appointment w.e.f 27 th January, 2025 as Non- Executive Director, subject to members approval. |
| 4. | Brief Profile (in case of appointment) | Tushar Awate holds the certificate of Bachelor in Management Studies from Mumbai University. He is a financial professional with a comprehensive 12 year track record in various financial domains. His expertise spans treasury management, FX hedging, financial analysis, and project financing. |
| 5. | Disclosure of relationships between Directors (in case of appointment of a Director) | Mr. Tushar Awate is not related to any Director on the Board. |

RAYMED LABS LIMITED

CIN: L24111UP1992PLC014240

Reg. off.-103 Emperor 1, Supertech Emerald Court, Sector 93A Noida,

UP – 201304, Website- www.raymedlab.com

E-mail- raymedlabs@rediffmail.com, Phone no. - 0120-2426900, 9412700300

“ANNEXURE – H”

Disclosure of information is pursuant to under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, read with SEBI Circular No. *SEBI/HO/CFD-PoD1/P/CIR/2023/123* date 13th July, 2023

| Sr. No | Particulars | Information |
|--------|--|---|
| 1. | Name of the Director | Urmila Hansraj Sharma |
| 2. | Reasons for change viz. appointment, reappointment, resignation, removal, death or otherwise | Re-appointment |
| 3. | Date of appointment/ cessation and terms of appointment | Re-appointment w.e.f 27 th January, 2025 as Non- Executive Director, subject to members approval. |
| 4. | Brief Profile (in case of appointment) | Urmila Sharma has completed her qualification from Holy Family Convent High School. She was born and raised in Igatpuri, Nashik District, after marriage she moved to Mumbai, where she embarked on a journey that combined her passion for cooking with entrepreneurship. Over the past 15 years, she has successfully established and managed a thriving catering business, catering to numerous functions and events in Mumbai. Her dedication to culinary excellence and customer satisfaction has been instrumental in building a strong reputation in the industry. |
| 5. | Disclosure of relationships between Directors (in case of appointment of a Director) | Mrs. Urmila Sharma is not related to any Director on the Board. |

Limited Review Report on the Unaudited Quarterly and year-to-date Standalone Financial Results of Raymed Labs Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To
The Board of Directors
Raymed Labs Limited

1. We have reviewed the accompanying statement of unaudited standalone Financial Results of **Raymed Labs Limited** ("the Company") for the quarter ended 31st December 2024 ("the statement"). This statement is being submitted to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. (Listing Regulations)
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India and in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For K T P S & Co.

Chartered Accountants

Firm's Registration No. 134942W



CA Anurag Khandelia
Partner

Mem. No. 172909

UDIN: 25172909BMIGDN9220

Place: Mumbai

Date: 27/01/2025

RAYMED LABS LIMITED

UNAUDITED BALANCE SHEET AS AT DECEMBER 31, 2024

(INR in Lakhs)

| Particulars | As at Dec 31, 2024 | As at March 31, 2024 |
|---|-----------------------|-------------------------|
| I ASSETS | | |
| 1. Non Current Assets | | |
| (a) Property, Plant and Equipment | 14.14 | 14.58 |
| (b) Capital Work-In-Progress | - | - |
| (c) Investment Property | - | - |
| (d) Intangible Assets | - | - |
| (e) Intangible Assets Under Development | - | - |
| (f) Financial Assets | - | - |
| (g) Income Tax Assets (Net) | - | - |
| (h) Other Non Current Assets | - | - |
| | <u>14.14</u> | <u>14.58</u> |
| 2. Current Assets | | |
| (a) Inventories | - | - |
| (b) Financial Assets | | |
| (i) Investments | - | - |
| (ii) Trade Receivables | - | - |
| (iii) Cash and Cash Equivalents | 55.79 | 0.05 |
| (iv) Other Bank Balances other than (iii) above | - | - |
| (v) Loans | 0.45 | 0.45 |
| (vi) Others | - | - |
| (c) Other Current Assets | - | - |
| | <u>56.24</u> | <u>0.50</u> |
| Total Assets | <u>70.38</u> | <u>15.08</u> |
| II EQUITY AND LIABILITIES | | |
| Equity | | |
| (a) Equity Share Capital | 427.35 | 427.35 |
| (b) Other Equity | (696.43) | (668.11) |
| | <u>(269.08)</u> | <u>(240.76)</u> |
| LIABILITIES | | |
| 1. Non Current Liabilities | | |
| (a) Financial Liabilities | | |
| (i) Borrowings | 327.13 | 243.17 |
| (b) Provisions | - | - |
| (c) Deferred Tax Liabilities (Net) | - | - |
| | <u>327.13</u> | <u>243.17</u> |
| 2. Current Liabilities | | |
| (a) Financial Liabilities | | |
| (i) Borrowings | - | - |
| (ii) Trade Payable | - | - |
| (iii) Other Financial Liabilities | 5.00 | 5.00 |
| (b) Other Current Liabilities | 7.34 | 7.66 |
| (c) Provisions | - | - |
| (d) Current Tax Liabilities (Net) | - | - |
| | <u>12.34</u> | <u>12.67</u> |
| Total Equity and Liabilities | <u>70.38</u> | <u>15.08</u> |

Summary of Significant Accounting Policies

The notes referred to above are an integral part of the financial statements

For and on behalf of the Board of Directors

Raymed Labs Limited



Prashant Bajaj

Director & Chairman

DIN- 06634046

Place: Mumbai

Dated: 27th January, 2025



RAYMED LABS LIMITED

STATEMENT OF UNAUDITED PROFIT AND LOSS FOR THE PERIOD ENDED DECEMBER 31, 2024

| Particulars | (INR in Lakhs) | | | | | |
|---|---|---|--|---|---|---|
| | For The qtr ended December 31, 2024 | For The qtr ended September 30, 2024 | For The qtr ended December 31, 2023 | For the nine month ended December 31, 2024 | For the nine month ended December 31, 2023 | For the Year ended March 31, 2024 |
| i Revenue | | | | | | |
| Revenue from Operations | - | - | - | - | - | - |
| Other Income | 0.86 | - | - | 0.86 | - | - |
| Total Income | 0.86 | - | - | 0.86 | - | - |
| ii Expenses | | | | | | |
| Purchases of Stock in Trade | - | - | - | - | - | - |
| Change in Inventories of Finished Goods/Work-in-progress/ Stock in Trade | - | - | - | - | - | - |
| Employee Benefits Expenses | 0.40 | 0.80 | 0.90 | 2.10 | 2.70 | 3.60 |
| Finance Costs | 0.00 | 0.00 | - | 0.00 | - | - |
| Depreciation and Amortization Expenses | 0.15 | 0.11 | 0.09 | 0.44 | 0.27 | 0.48 |
| Other Expenses | 25.22 | 0.74 | 0.96 | 26.65 | 2.26 | 6.09 |
| Total Expenses | 25.77 | 1.66 | 1.95 | 29.20 | 5.23 | 10.16 |
| III Profit before tax (I- II) | (24.91) | (1.66) | (1.95) | (28.33) | (5.23) | (10.16) |
| IV Less: Tax Expense: | | | | | | |
| Current Tax | - | - | - | - | - | - |
| MAT Credit Entitlement | - | - | - | - | - | - |
| Deferred Tax | - | - | - | - | - | - |
| Total Tax Expense | - | - | - | - | - | - |
| V Profit for the Year (III-IV) | (24.91) | (1.66) | (1.95) | (28.33) | (5.23) | (10.16) |
| VI Other Comprehensive Income | | | | | | |
| <u>Items that will not be reclassified to profit or loss</u> | | | | | | |
| Re-measurement gains/ (losses) on defined benefit obligations | - | - | - | - | - | - |
| Tax Effect on above | - | - | - | - | - | - |
| Other Comprehensive Income for the year, net of tax | - | - | - | - | - | - |
| VII Total Comprehensive Income for the year (V+VI) (Comprising Profit and Other Comprehensive Income for the year) | (24.91) | (1.66) | (1.95) | (28.33) | (5.23) | (10.16) |
| VIII Earnings Per Equity Share (Face Value INR 10 Per Share): | | | | | | |
| Basic and Diluted (INR) | (0.58) | (0.04) | (0.05) | (0.66) | (0.12) | (0.24) |

Summary of Significant Accounting Policies

The notes referred to above are an integral part of the financial statements

For and on behalf of the Board of Directors
Raymed Labs Limited


Prashant Bajaj
Director & Chairman
DIN- 06634046
Place: Mumbai
Dated: 27th January, 2025



RAYMED LABS LIMITED
Unaudited Cash Flow Statement for the period ended 31.12.2024

| Particulars | For the Year ended Dec 31, 2024 | For the Year ended March 31, 2024 |
|---|------------------------------------|--------------------------------------|
| A. Cash Flow from Operating Activities | | |
| Net Profit Before Tax | (28.33) | (10.16) |
| Adjustments: | | |
| Depreciation and Amortization of Property, Plant and Equipment | 0.44 | 0.48 |
| Loss on Sale of property, plant and equipment (net) | - | - |
| Other Non Cash Items | | 3.84 |
| Fees on Guarantee given on behalf of the Subsidiary Company | | |
| Finance Costs (Including Fair Value Change in Financial Instruments) | 0.00 | - |
| Operating cash flows before working capital changes | (27.89) | (5.85) |
| <u>Adjustments for Changes in Working Capital</u> | | |
| Decrease/ (Increase) in Inventories | - | - |
| Decrease/ (Increase) in Trade receivables | - | - |
| Decrease/ (Increase) in Current Loans | - | - |
| Decrease/ (Increase) in Non-Current Financial Assets - Others | - | - |
| Decrease/ (Increase) in Other Current Financial Assets | - | - |
| Decrease/ (Increase) in Other Current Assets | - | - |
| Increase/ (Decrease) in Trade Payables | - | (0.22) |
| Increase/ (Decrease) in Current Financial Liabilities - Other | - | - |
| Increase/ (Decrease) in Other Current Liabilities | (0.33) | - |
| Increase/ (Decrease) in Non-Current Provisions | - | - |
| Increase/ (Decrease) in Current Provisions | - | - |
| Cash generated from operations | (28.22) | (6.07) |
| Income taxes paid | | |
| Net cash flow from operating activities | (28.22) | (6.07) |
| Less : Finance cost paid | (0.00) | - |
| Net cash flow(Used in) from operating activities (A) | (28.22) | (6.07) |
| B. Cash Flow from Investing Activities | | |
| Purchase or construction of property, plant and equipment (including capital work-in-progress and capital advances) | - | - |
| Proceeds from/ (Investment in) fixed deposits (net) | - | - |
| Proceeds from/ (Investment in) Other Bank Balances | - | - |
| Proceeds from sale of property, plant and equipment | - | - |
| Purchase or construction of Investment Properties | - | - |
| Loan taken / (Repayment) of Loan | 83.96 | 6.07 |
| Interest Received | - | - |
| Dividend Received | - | - |
| Net cash flow from/ (used in) investing activities (B) | 83.96 | 6.07 |
| C. Cash Flow from Financing Activities | | |
| Increase/(Decrease) Non-Current Financial Liabilities - Borrowings | - | - |
| Increase/(Decrease)Bank Overdraft | - | - |
| Proceeds from public issue of shares | - | - |
| Proceeds from securities premium (net of QIP expenses) | - | - |
| Net cash flow from financing activities © | - | - |
| Net cash Increase/(decrease) in cash and cash equivalents (A+B+C) | 55.73 | 0.00 |
| Cash and cash equivalents at the beginning of the year (Refer Note 9) | 0.05 | 0.05 |
| Cash and cash equivalents at the end of the year (Refer Note 9) | 55.79 | 0.05 |
| Net cash Increase/(decrease) in cash and cash equivalent | 55.73 | - |

The notes referred to above are an integral part of the financial statements.
As per our report of even date

For and on behalf of the Board of Directors
Raymed Labs Limited


Prashant Bajaj
Director & Chairman
DIN- 06634046
Place: Mumbai
Dated: 27th January, 2025



Date: 27-01-2025

To,
The Board of Directors,
Raymed Labs Limited
C-273, Sector 63, Noida,
Gautam Buddha Nagar,
Uttar Pradesh, 201301

Subject – Resignation from the Post of Director of the Company

Dear Sir,

With reference to above captioned subject, I hereby tender my resignation from the Post of the Director of the Company due to some personal exigencies.


Hence, I request the Board members to kindly accept my resignation and relieve me from my duties.

I hereby confirm that there are no material reasons other than those mentioned above for my resignation.

I wish to place on record my gratitude and appreciation to esteemed Board members for their continuous support and guidance.

Kindly acknowledge the receipt of this resignation letter and arrange to submit the necessary forms with the Office of the Registrar of Companies and Stock Exchange.

Thanking you
Yours Sincerely.



Nisha Goyal
Director
DIN: 02710946

Date: 27-01-2025

To,
The Board of Directors,
Raymed Labs Limited
C-273, Sector 63, Noida,
Gautam Buddha Nagar,
Uttar Pradesh, 201301

Subject – Resignation from the Post of Whole-time Director of the Company

Dear Sir,

With reference to above captioned subject, I hereby tender my resignation from the Post of the Whole-time Director of the Company due to some personal exigencies.

Hence, I request the Board members to kindly accept my resignation and relieve me from my duties.


I hereby confirm that there are no material reasons other than those mentioned above for my resignation.

I wish to place on record my gratitude and appreciation to esteemed Board members for their continuous support and guidance.

Kindly acknowledge the receipt of this resignation letter and arrange to submit the necessary forms with the Office of the Registrar of Companies and Stock Exchange.

Thanking you

Yours Sincerely.



Ajai Goyal
Whole-time Director
DIN: 02636418

Date: 23.01.2025

To,
The Board of Directors,
Raymed Labs Limited
C-273, Sector 63, Noida,
Gautam Buddha Nagar,
Uttar Pradesh, 201301

Subject – Resignation from the Post of Internal Auditor of the Company

Dear Sir,

With reference to above captioned subject, I hereby tender my resignation from the Post Internal Auditor of the Company with the mutual consent of the Board of Directors of the Company.

Hence, I request the Board members to kindly accept my resignation and relieve me from duties.


I hereby confirm that there are no material reasons other than those mentioned above for my resignation.

I wish to place on record my gratitude and appreciation to esteemed Board members for their continuous support and guidance.

Kindly acknowledge the receipt of this resignation letter and arrange to submit the necessary forms with the Office of the Registrar of Companies and Stock Exchange.

Thanking you

Yours Sincerely.



Nisha Goyal
Internal Auditor